Bellicum Pharmaceuticals (NASDAQ:BLCM) : Traders are bullish on Bellicum Pharmaceuticals (NASDAQ:BLCM) as it has outperformed the S&P 500 by a wide margin of 14.04% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.77%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 10.16% in the last 1 week, and is up 15.88% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -26.12% from its 1 Year high price. On Nov 30, 2015, the shares registered one year high at $23.84 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $12.53 and the 200 Day Moving Average price is recorded at $11.60.
The stock has recorded a 20-day Moving Average of 16.72% and the 50-Day Moving Average is 30.59%.
Bellicum Pharmaceuticals (NASDAQ:BLCM): stock turned positive on Friday. Though the stock opened at $14.72, the bulls momentum made the stock top out at $15.465 level for the day. The stock recorded a low of $14.69 and closed the trading day at $14.96, in the green by 1.70%. The total traded volume for the day was 768,644. The stock had closed at $14.71 in the previous days trading.
In an insider trading activity, Moseley Annemarie, officer (COO/EVP Clinical Development) of Bellicum Pharmaceuticals, Inc, unloaded 25,000 shares at an average price of $13 on June 2, 2016. The total amount of the transaction was worth $325,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy, and dendritic cell vaccines. The Companys product candidates include BPX-501, BPX-201, BPX-401, BPX-601 and BPX-701. It is also engaged in other development programs, such as CIDeCAR for the treatment of solid tumors and CaspaCIDe TCR for the treatment of hematological cancers.